ML
Moulder Leon O Jr
董事
BoardM
内部人交易记录
董事基于 11 个已确定 T+90 收益的买入信号。收益基准:公布次日的收盘价。
Discover the detailed record of transactions filed by Moulder Leon O Jr, 董事. Director active across 3 companies, notably Zai Lab Ltd. Aggregated, 18 reports have been logged. Split: 11 buys · 0 sell. Total volume traded: €4.7m. Activity tracked since 3 January 2022. The latest transaction was filed on 28 April 2026 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Moulder Leon O Jr
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报18 总计
25,000 股@ US$18.020.023% mcap24.1% 占其流量Common StockSEC:0001104659-26-051889:0
35,000 股@ US$17.620.031% mcap33.1% 占其流量Common StockSEC:0001104659-26-051889:1
20,000 股@ US$18.2312.8% 占其流量Common StockSEC:0001104659-26-038031:0
34,000 股@ US$19.3122.9% 占其流量Common StockSEC:0001104659-26-038031:1
57,000 股@ US$17.9618.4% 占其流量Common StockSEC:0001104659-26-009756:0
50,000 股@ US$16.3814.9% 占其流量Common StockSEC:0001104659-26-002589:0
36,928 股@ US$20.8521.0% 占其流量Common StockSEC:0001104659-25-098413:0
10,831 股0American Depositary SharesSEC:0000905148-25-002219:0
25,000 股@ US$6.6723.3% 占其流量Common StockSEC:0001104659-25-015145:0
25,000 股@ US$10.7637.5% 占其流量Common StockSEC:0001104659-24-125677:0
7,500 股@ US$15.0015.6% 占其流量Common StockSEC:0001104659-24-121081:0
10,000 股@ US$17.9123.6% 占其流量Common StockSEC:0001104659-24-101773:0
164,523 股Common StockSEC:0001104659-24-100765:0
164,523 股Common StockSEC:0001104659-24-100325:0
21,253 股0American Depositary SharesSEC:0000905148-24-001750:0
166,667 股@ US$12.00100.0% 占其流量Common StockSEC:0000950170-24-007137:0
18,903 股@ US$26.45100.0% 占其流量American Depositary SharesSEC:0000950170-23-031100:0
7,763 股0Ordinary SharesSEC:0001567619-22-000398:0
About Moulder Leon O Jr
MOULDER LEON O JR is Administrateur. He has 18 filings in total, and across the 18 sampled filings between 2022-01-04 and 2026-04-29, buys total 4706064 EUR and sells total 0 EUR. His listed companies are Zenas BioPharma, Inc., where he is Chief Executive Officer, Zai Lab Ltd, where he is Director, and Dianthus Therapeutics, Inc. /DE/, where he is Director.